Trade Black Diamond Therapeutics, Inc. - BDTX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0270 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 20% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Black Diamond Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 4.7715 |
Open* | 4.8615 |
1-Year Change* | 204.3% |
Day's Range* | 4.6915 - 4.8915 |
52 wk Range | 1.22-6.85 |
Average Volume (10 days) | 389.12K |
Average Volume (3 months) | 9.41M |
Market Cap | 140.96M |
P/E Ratio | -100.00K |
Shares Outstanding | 51.64M |
Revenue | N/A |
EPS | -2.13 |
Dividend (Yield %) | N/A |
Beta | 2.58 |
Next Earnings Date | Mar 7, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 18, 2024 | 4.6915 | -0.0900 | -1.88% | 4.7815 | 4.9315 | 4.6515 |
Mar 15, 2024 | 4.7715 | 0.2100 | 4.60% | 4.5615 | 5.0015 | 4.4915 |
Mar 14, 2024 | 4.5115 | 0.3200 | 7.63% | 4.1915 | 4.6315 | 4.1415 |
Mar 13, 2024 | 4.1815 | 0.4100 | 10.87% | 3.7715 | 4.2515 | 3.6915 |
Mar 12, 2024 | 3.7615 | -0.1800 | -4.57% | 3.9415 | 3.9815 | 3.6915 |
Mar 11, 2024 | 3.9815 | -0.0300 | -0.75% | 4.0115 | 4.1715 | 3.9515 |
Mar 8, 2024 | 4.0615 | -0.1000 | -2.40% | 4.1615 | 4.4215 | 4.0415 |
Mar 7, 2024 | 4.1815 | -0.1800 | -4.13% | 4.3615 | 4.5515 | 4.1515 |
Mar 6, 2024 | 4.4115 | 0.1000 | 2.32% | 4.3115 | 4.5215 | 4.3115 |
Mar 5, 2024 | 4.3915 | 0.0300 | 0.69% | 4.3615 | 4.4815 | 4.3015 |
Mar 4, 2024 | 4.4915 | -0.3100 | -6.46% | 4.8015 | 4.8515 | 4.4515 |
Mar 1, 2024 | 4.7615 | -0.3700 | -7.21% | 5.1315 | 5.3215 | 4.6515 |
Feb 29, 2024 | 5.1315 | -0.0100 | -0.19% | 5.1415 | 5.2515 | 4.9515 |
Feb 28, 2024 | 4.9315 | 0.0900 | 1.86% | 4.8415 | 5.5615 | 4.8015 |
Feb 27, 2024 | 4.8815 | -0.0100 | -0.20% | 4.8915 | 5.0515 | 4.7915 |
Feb 26, 2024 | 4.8715 | 0.1900 | 4.06% | 4.6815 | 4.9815 | 4.6815 |
Feb 23, 2024 | 4.6815 | 0.2500 | 5.64% | 4.4315 | 4.7515 | 4.4215 |
Feb 22, 2024 | 4.4815 | -0.0900 | -1.97% | 4.5715 | 4.7615 | 4.4415 |
Feb 21, 2024 | 4.6615 | -0.1000 | -2.10% | 4.7615 | 4.9215 | 4.5415 |
Feb 20, 2024 | 4.8515 | -0.3000 | -5.82% | 5.1515 | 5.6315 | 4.6315 |
Black Diamond Therapeutics, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, May 7, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q1 2024 Black Diamond Therapeutics Inc Earnings Release Q1 2024 Black Diamond Therapeutics Inc Earnings ReleaseForecast -Previous - |
Wednesday, May 15, 2024 | ||
Time (UTC) 13:00 | Country US
| Event Black Diamond Therapeutics Inc Annual Shareholders Meeting Black Diamond Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 92.828 | 126.872 | 69.57 | 29.332 | 8.904 |
Selling/General/Admin. Expenses, Total | 28.391 | 30.043 | 21.361 | 7.579 | 1.954 |
Research & Development | 64.437 | 96.829 | 48.209 | 21.753 | 6.95 |
Unusual Expense (Income) | 0 | ||||
Operating Income | -92.828 | -126.872 | -69.57 | -29.332 | -8.904 |
Interest Income (Expense), Net Non-Operating | -0.219 | 3.464 | 4.041 | -5.932 | -0.011 |
Other, Net | -0.354 | -2.188 | -1.725 | 0.006 | -0.016 |
Net Income Before Taxes | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Net Income After Taxes | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Net Income Before Extra. Items | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Net Income | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Income Available to Common Excl. Extra. Items | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Income Available to Common Incl. Extra. Items | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Diluted Net Income | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Diluted Weighted Average Shares | 36.3256 | 36.189 | 32.9071 | 32.6364 | 32.6364 |
Diluted EPS Excluding Extraordinary Items | -2.50977 | -3.47056 | -2.04375 | -1.08033 | -0.27365 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Diluted Normalized EPS | -2.57122 | -3.47056 | -2.04375 | -1.08033 | -0.27365 |
Gain (Loss) on Sale of Assets | 2.232 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 20.032 | 21.561 | 21.852 | 22.124 | 23.173 |
Selling/General/Admin. Expenses, Total | 6.878 | 6.808 | 7.243 | 6.277 | 6.978 |
Research & Development | 13.154 | 14.753 | 14.609 | 15.847 | 16.195 |
Operating Income | -20.032 | -21.561 | -21.852 | -22.124 | -23.173 |
Interest Income (Expense), Net Non-Operating | 0.539 | 0.622 | -1.573 | 0.562 | 0.386 |
Other, Net | 0.341 | 0.064 | 0.115 | -0.092 | -0.143 |
Net Income Before Taxes | -19.152 | -20.875 | -21.078 | -21.654 | -22.93 |
Net Income After Taxes | -19.152 | -20.875 | -21.078 | -21.654 | -22.93 |
Net Income Before Extra. Items | -19.152 | -20.875 | -21.078 | -21.654 | -22.93 |
Net Income | -19.152 | -20.875 | -21.078 | -21.654 | -22.93 |
Income Available to Common Excl. Extra. Items | -19.152 | -20.875 | -21.078 | -21.654 | -22.93 |
Income Available to Common Incl. Extra. Items | -19.152 | -20.875 | -21.078 | -21.654 | -22.93 |
Diluted Net Income | -19.152 | -20.875 | -21.078 | -21.654 | -22.93 |
Diluted Weighted Average Shares | 36.5161 | 36.4839 | 36.3902 | 36.3462 | 36.2939 |
Diluted EPS Excluding Extraordinary Items | -0.52448 | -0.57217 | -0.57922 | -0.59577 | -0.63179 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.52448 | -0.57217 | -0.64056 | -0.59577 | -0.63179 |
Gain (Loss) on Sale of Assets | 2.232 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 127.706 | 215.703 | 319.554 | 155.714 | 51.684 |
Cash and Short Term Investments | 122.807 | 209.786 | 315.067 | 154.666 | 51.66 |
Cash & Equivalents | 34.315 | 65.799 | 34.605 | 154.666 | 51.66 |
Prepaid Expenses | 4.899 | 5.917 | 4.487 | 1.048 | 0.024 |
Total Assets | 156.255 | 247.682 | 329.67 | 158.295 | 51.826 |
Property/Plant/Equipment, Total - Net | 27.381 | 30.74 | 8.787 | 0.164 | 0.134 |
Property/Plant/Equipment, Total - Gross | 28.131 | 31.109 | 8.951 | 0.276 | 0.234 |
Accumulated Depreciation, Total | -0.75 | -0.369 | -0.164 | -0.112 | -0.1 |
Other Long Term Assets, Total | 1.168 | 1.239 | 1.329 | 2.417 | 0.008 |
Total Current Liabilities | 15.261 | 23.642 | 14.218 | 4.863 | 2.575 |
Accounts Payable | 1.877 | 4.107 | 2.538 | 1.964 | 0.416 |
Accrued Expenses | 13.384 | 19.535 | 11.68 | 2.899 | 0.452 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 1.707 | |||
Total Liabilities | 40.56 | 51.782 | 21.912 | 4.879 | 6.598 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 25.299 | 28.14 | 7.694 | 0.016 | 4.023 |
Total Equity | 115.695 | 195.9 | 307.758 | 153.416 | 45.228 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 60.77 | ||
Common Stock | 0.005 | 0.005 | 0.005 | 0.001 | 0.001 |
Additional Paid-In Capital | 452.503 | 440.129 | 425.363 | 3.812 | 0.169 |
Retained Earnings (Accumulated Deficit) | -334.989 | -243.82 | -118.224 | -50.97 | -15.712 |
Total Liabilities & Shareholders’ Equity | 156.255 | 247.682 | 329.67 | 158.295 | 51.826 |
Total Common Shares Outstanding | 36.4343 | 36.2346 | 36.0784 | 32.6364 | 32.6364 |
Redeemable Preferred Stock | 0 | 0 | 200.573 | ||
Short Term Investments | 88.492 | 143.987 | 280.462 | ||
Other Equity, Total | -0.414 | 0.614 | |||
Unrealized Gain (Loss) | -1.824 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 147.049 | 92.992 | 107.977 | 127.706 | 150.978 |
Cash and Short Term Investments | 144.256 | 89.527 | 103.366 | 122.807 | 144.181 |
Cash & Equivalents | 57.978 | 41.888 | 39.141 | 34.315 | 53.96 |
Short Term Investments | 86.278 | 47.639 | 64.225 | 88.492 | 90.221 |
Prepaid Expenses | 2.793 | 3.465 | 4.611 | 4.899 | 6.797 |
Total Assets | 172.382 | 119.879 | 135.582 | 156.255 | 180.416 |
Property/Plant/Equipment, Total - Net | 24.514 | 25.659 | 26.437 | 27.381 | 28.27 |
Property/Plant/Equipment, Total - Gross | 25.252 | 26.618 | 27.282 | 28.131 | 28.98 |
Accumulated Depreciation, Total | -0.738 | -0.959 | -0.845 | -0.75 | -0.71 |
Other Long Term Assets, Total | 0.819 | 1.228 | 1.168 | 1.168 | 1.168 |
Total Current Liabilities | 15.066 | 13.898 | 12.847 | 15.261 | 21.143 |
Accounts Payable | 0.694 | 2.737 | 3.046 | 1.877 | 5.76 |
Accrued Expenses | 14.372 | 11.161 | 9.801 | 13.384 | 15.383 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 38.065 | 37.68 | 37.392 | 40.56 | 47.185 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 22.999 | 23.782 | 24.545 | 25.299 | 26.042 |
Total Equity | 134.317 | 82.199 | 98.19 | 115.695 | 133.231 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.007 | 0.005 | 0.005 | 0.005 | 0.005 |
Additional Paid-In Capital | 532.697 | 457.871 | 455.225 | 452.503 | 449.625 |
Retained Earnings (Accumulated Deficit) | -398.023 | -375.016 | -355.864 | -334.989 | -313.911 |
Other Equity, Total | -0.364 | -0.661 | -1.176 | -1.824 | -2.488 |
Total Liabilities & Shareholders’ Equity | 172.382 | 119.879 | 135.582 | 156.255 | 180.416 |
Total Common Shares Outstanding | 51.6352 | 36.5335 | 36.512 | 36.4343 | 36.3662 |
Redeemable Preferred Stock |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
Cash From Operating Activities | -85.082 | -100.148 | -52.146 | -24.674 | -8.454 |
Cash From Operating Activities | 0.508 | 0.205 | 0.052 | 0.047 | 0.044 |
Non-Cash Items | 15.48 | 18.223 | 10.014 | 10.074 | 0.079 |
Changes in Working Capital | -9.901 | 7.02 | 5.042 | 0.463 | 0.354 |
Cash From Investing Activities | 53.366 | 130.613 | -281.691 | -0.021 | -0.076 |
Capital Expenditures | -0.192 | -2.71 | -0.142 | -0.021 | -0.076 |
Other Investing Cash Flow Items, Total | 53.558 | 133.323 | -281.549 | 0 | |
Cash From Financing Activities | 0.177 | 0.729 | 214.944 | 127.756 | 52.312 |
Financing Cash Flow Items | 0 | -1.743 | 0 | ||
Issuance (Retirement) of Stock, Net | 0.177 | 0.729 | 214.944 | 129.499 | 52.312 |
Issuance (Retirement) of Debt, Net | 0 | ||||
Net Change in Cash | -31.539 | 31.194 | -118.893 | 103.061 | 43.782 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -20.875 | -91.169 | -70.091 | -48.437 | -25.507 |
Cash From Operating Activities | -20.031 | -85.082 | -63.143 | -46.667 | -28.6 |
Cash From Operating Activities | 0.122 | 0.508 | 0.382 | 0.253 | 0.125 |
Non-Cash Items | 3.507 | 15.48 | 11.804 | 8.366 | 4.293 |
Changes in Working Capital | -2.785 | -9.901 | -5.238 | -6.849 | -7.511 |
Cash From Investing Activities | 24.806 | 53.366 | 51.044 | 36.537 | 16.729 |
Capital Expenditures | 0 | -0.192 | -0.192 | -0.2 | -0.007 |
Other Investing Cash Flow Items, Total | 24.806 | 53.558 | 51.236 | 36.737 | 16.736 |
Cash From Financing Activities | 0.051 | 0.177 | 0.205 | 0.153 | 0.153 |
Issuance (Retirement) of Stock, Net | 0.051 | 0.177 | 0.205 | 0.153 | 0.153 |
Net Change in Cash | 4.826 | -31.539 | -11.894 | -9.977 | -11.718 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Bellevue Asset Management AG | Investment Advisor | 16.5502 | 8535839 | 400000 | 2023-10-17 | LOW |
Versant Ventures | Venture Capital | 12.5047 | 6449348 | 0 | 2023-03-15 | LOW |
New Enterprise Associates (NEA) | Venture Capital | 8.6257 | 4448757 | 1000000 | 2023-06-30 | LOW |
RA Capital Management, LP | Hedge Fund | 6.8361 | 3525754 | 935850 | 2023-06-30 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 3.968 | 2046517 | 400000 | 2023-06-30 | MED |
Boxer Capital, L.L.C. | Hedge Fund | 3.9066 | 2014858 | 0 | 2023-06-30 | LOW |
Point72 Asset Management, L.P. | Hedge Fund | 3.8778 | 2000000 | 2000000 | 2023-06-30 | HIGH |
Deerfield Management Company, L.P. | Hedge Fund | 3.49 | 1800000 | 1800000 | 2023-06-30 | MED |
RTW Investments L.P. | Investment Advisor/Hedge Fund | 3.2961 | 1700000 | 1700000 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.8723 | 1481385 | 723800 | 2023-06-30 | LOW |
Citadel Advisors LLC | Hedge Fund | 2.3566 | 1215408 | 657637 | 2023-06-30 | LOW |
J.P. Morgan Securities LLC | Research Firm | 2.0931 | 1079507 | 1079507 | 2023-06-30 | MED |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 1.8323 | 945039 | 761641 | 2023-06-30 | LOW |
Epstein (David M) | Individual Investor | 1.7712 | 913479 | -25000 | 2023-06-27 | LOW |
Ally Bridge Group NY LLC | Hedge Fund | 1.5511 | 800000 | 800000 | 2023-06-30 | HIGH |
Kennedy Capital Management, Inc. | Investment Advisor | 1.4569 | 751403 | 751403 | 2023-06-30 | MED |
Heights Capital Management, Inc. | Investment Advisor | 1.4542 | 750000 | 750000 | 2023-06-30 | HIGH |
Cowen Investment Management LLC | Investment Advisor/Hedge Fund | 1.4542 | 750000 | 750000 | 2023-06-30 | HIGH |
Driehaus Capital Management, LLC | Investment Advisor/Hedge Fund | 1.3514 | 696969 | 685952 | 2023-06-30 | MED |
Rock Springs Capital Management LP | Hedge Fund | 1.0921 | 563233 | 563233 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Black Diamond Therapeutics, Inc. Company profile
Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.Industry: | Bio Therapeutic Drugs |
One Main Street, 14th Floor
CAMBRIDGE
MASSACHUSETTS 02142
US
Income Statement
- Annual
- Quarterly
News
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?
UK banks will be in the spotlight in the week ahead as the European earnings season continues
16:38, 16 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com